New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 13, 2014
10:33 EDTZU, RAX, MNKD, ARWR, OLED, ICPT, RPTP, VNDA, UBNTOptions with decreasing implied volatility
Options with decreasing implied volatility: RPTP ARWR ZU ICPT MNKD UBNT OLED RAX UVXY VNDA
News For RPTP;ARWR;ZU;ICPT;MNKD;UBNT;OLED;RAX;VNDA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 >>
August 20, 2015
17:19 EDTRPTPRaptor Pharmaceuticals' expanded label for Procysbi approved by FDA
Subscribe for More Information
09:47 EDTMNKDMannKind failed to settle loan by deadline, TheStreet's Feuerstein says
Subscribe for More Information
August 19, 2015
11:01 EDTMNKDStocks with call strike movement; MNKD SUNE
MannKind (MNKD) November 4.5 call option implied volatility increased 3% to 81, SunEdison (SUNE) January 16 call option implied volatility decreased 1% to 73 according to IVolatility.
August 18, 2015
07:28 EDTZULiberty Interactive acquisition positive, says Wells Fargo
Subscribe for More Information
August 17, 2015
16:53 EDTZUOn The Fly: Top stock stories for Monday
Subscribe for More Information
13:30 EDTZUOn The Fly: Top stock stories at midday
Stocks began the session deep in negative territory after a disappointing Empire Manufacturing report. The data got the market off to a weak start as optimism over last week's finish began to fade. The averages continued to drift in a narrow range for the opening hour before reversing and capturing the opening losses. Each of the major equity indices is now back in positive territory sporting slight gains across the board. ECONOMIC EVENTS: In the U.S., the Empire State manufacturing index plunged to -14.92 in August after rebounding to 3.86 in July from June's -1.98. The consensus estimate was 4.75, and the surprising drop puts the index at its lowest point since April 2009. The employment component slid to 1.82, while new orders crashed to -15.70. Meanwhile, the U.S. NAHB homebuilder sentiment index rose to 61 in August from 60 in June and and is the highest since November 2005. The single family sales index edged up to 66 versus a revised 65 last month, while the index of prospective buyer traffic improved to 45 versus 43 previously. In Europe, various Eurozone parliaments prepare to vote on Greece's new EUR86B bailout plan this week. COMPANY NEWS: Liberty Interactive (QVCA) announced this morning an agreement to acquire zulily (ZU) for $18.75 per share in a deal valuing the online shopping site at $2.4B, driving zulily shares up more than 47% in intraday trading. The acquisition will be attributed to Liberty's QVC Group tracking stock, though QVC and zulily will be operated as separate consumer facing brands. On a conference call discussing the acquisition, Liberty Interactive executives noted that the "highly efficient" deal will allow Liberty to reach a younger base. MAJOR MOVERS: Among the notable gainers AVEO Oncology (AVEO), which rose roughly 50% after announcing a license agreement with Novartis (NVS) for the development and commercialization of AVEO's AV-380 drug and related antibodies. Also higher was Kite Pharma (KITE), which advanced roughly 5.4% after clarifying that an earlier patient death in its Phase 1/2 KTE-C19 trial for non-Hodgkin's lymphoma was unrelated to Kite's therapy. Additionally, shares of Target (TGT) have gained roughly 10c despite lingering in negative territory early Monday after the company promoted CFO John Mulligan to the newly created role of EVP and COO and appointed Cathy Smith as EVP and CFO. Prior to joining Target, Smith served as EVP and CFO at St. Louis-based Express Scripts (ESRX). Among the noteworthy losers was KKR (KKR), which lost roughly 2.4% after Samson Resources announced a restructuring agreement late Friday, adding that it expects to file for bankruptcy within 30 days. Also lower was Estee Lauder (EL), which declined nearly 6.5% after its quarterly guidance missed analysts' estimates. INDEXES: Near midday, The Dow was up 65.11, or 0.37%, to 17,542.51, the Nasdaq gained 34.73, or 0.69%, to 5,082.96, and the S&P 500 advanced 8.80, or 0.42%, to 2,101.03.
13:11 EDTZUAlibaba unlikely to make competing offer for zulily, say Baird
zulily (ZU) shareholder Alibaba (BABA) is unlikely to make a competing takeover bid for the online retailer, Baird analyst Colin Sebastian tells investors in a research note. Alibaba, which upped its stake in zulily to 9% in May, likely views the company as an investment rather than a vehicle to enter the U.S. market, Sebastian argues. This morning, Liberty Interactive (QVCA) announced it had reached an agreement to acquire zulily for $18.75 per share or $2.4B. The analyst sees strategic benefits from the deal. Increased takeover activity in the small-cap internet space could support the valuations of the remaining independents, including ChannelAdvisor (ECOM), Yelp (YELP), Groupon (GRPN), Angie's List (ANGI) and RetailMeNot (SALE), Sebastian writes. Shares of zulily are soaring 47% to $18.50 following the takeover agreement.
10:21 EDTRAX, ZUOptions with decreasing implied volatility
Subscribe for More Information
09:56 EDTZULiberty Interactive CEO says to stay 'far away' from Amazon's business model
09:55 EDTZULiberty Interactive CEO says sees strong growth trajectory for zulily
Subscribe for More Information
09:54 EDTZULiberty Interactive CEO Maffei says zulily a 'great natural fit' for company
Subscribe for More Information
09:24 EDTZULiberty Interactive zulily acquisition a 'highly efficient' use of capital
Subscribe for More Information
08:26 EDTZUZulily volatility low into Liberty Interactive acquiring in deal valued at $2.4B
Subscribe for More Information
08:26 EDTZULiberty Interactive to acquire zulily for $2.4B
08:04 EDTZULiberty Interactive to acquire zulily for $18.75 per share, deal valued at $2.4B
Subscribe for More Information
08:03 EDTZULiberty Interactive to acquire zulily for $18.75 per share
07:07 EDTRPTPRaptor Pharmaceuticals receives FDA approval of expanded label for Procysbi
Raptor Pharmaceutical announced that the FDA approved the expanded use of Procysbi delayed-release capsules to treat children two to six years of age with nephropathic cystinosis. The approved supplement was based on efficacy and safety data from an ongoing long-term extension study in which a cohort of children aged 2 to 6 years were enrolled and treated with Procysbi for 12 months. Additionally, data submitted as part of this supplement supported the long-term maintenance of white blood cell cystine levels and renal function in all age groups studied during extended treatment with Procysbi. Procysbi is now approved for the treatment of nephropathic cystinosis in adult and in pediatric patients 2 years of age and older in the U.S.
06:22 EDTARWRPiper's Tenthoff sees select biotech names outperforming in second half
Piper Jaffray analyst Edward Tenthoff expects drug launches, clinical data read-outs and potential partnerships to drive outperformance for select biotech names in the second half of 2015. Despite some recent profit-taking, 2015 has been another strong year for biotech stocks, Tenthoff tells investors in a research note. Names with important second half of the year catalysts include Vertex (VRTX), Regeneron (REGN), Seattle Genetics (SGEN), Exelixis (EXEL), Sarepta (SRPT), Novavax (NVAX), Arrowhead (ARWR), Array BioPharma (ARRY), Alnylam (ALNY), Genocea (GNCA), CymaBay (CBAY), Idera Pharmaceuticals (IDRA), Vitae Pharmaceuticals (VTAE).
August 14, 2015
10:24 EDTRAXOptions with decreasing implied volatility
Subscribe for More Information
07:37 EDTRAXJANA reports new stakes in Allergan, TWC, sells Applied Materials
Subscribe for More Information
1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use